Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Metastatic Triple-negative Breast Cancer

• Status: Terminated
• Trial end date: 2020-12-15
• Target enrollment: 0
• Participant gender: Female

Summary

Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Sun Yat-sen University
• Treatments: Albumin-Bound Paclitaxel; Carboplatin; Cyclophosphamide; Paclitaxel

Criteria

Inclusion Criteria:

• Eastern Cooperative Oncology Group (ECOG) 0 or 1.

• Histologically or cytologically proven diagnosis of breast cancer with evidence of locally recurrent or metastatic disease.

• Documentation of estrogen and progestin receptor (ER/PR) negative status and HER2/neu receptor negative status (ie, FISH negative or immunohistochemistry 0 or +1).

• Obtained complete response or Good partial response after first line chemotherapy.

• Normal organ function required prior to study entry.

• Willingness to comply with treatment plans and other study procedures.

Exclusion Criteria:

• Uncontrolled central nervous system (CNS) involvement with disease

• Fertile women unwilling to use contraceptive techniques during treatment

• Females who are pregnant

• Organ dysfunction.

• Patients may not be receiving any other investigational agents.